# BioApp

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioapp

- Industry: Biotechnology
- Headquarters: Gyeongsangbuk-do, South Korea
- Website: www.bioapp.co.kr
- Total disclosed funding: $15M
- Latest round: Series C (Mar 21, 2020)
- Investors on record: 6

## About

Based in Pohang, South Korea, and founded in 2011, BioApplications Inc., trading under the name BioApp, operates as a vaccine development company. In July 2022, BioApp raised KRW 4.9 billion in series D funding from Posco International.

BioApp provides vaccinations for both human and animal diseases, including the COVID-19 and swine fever vaccines. The company also provides Green Vaccine, a vaccine made from plant proteins extracted and refined using plant protein platform technology.

The company will use the 2022 funding to expand its factory, invest in equipment, and conduct domestic clinical trials for vaccines against swine fever and avian influenza.

## Funding rounds

- Series C, Mar 21, 2020, $6M — CKD Venture Capital, Posco Investment, WONIK Investment Partners, Daekyo Investment, DT&Investment, BNK Venture Capital
- Series B, Aug 7, 2018, $4.9M — CKD Venture Capital, Posco Investment, Daekyo Investment, BNK Venture Capital
- Series A, Jul 19, 2017, $4.5M — Posco Investment, WONIK Investment Partners, Daekyo Investment, DT&Investment

## Investors

- Posco Investment (https://capitalatlas.ai/funds/posco-investment) — Series A, Series B, Series C
- WONIK Investment Partners (https://capitalatlas.ai/funds/wonik-investment-partners) — Series A, Series C
- Daekyo Investment (https://capitalatlas.ai/funds/daekyo-investment) — Series A, Series B, Series C
- DT&Investment (https://capitalatlas.ai/funds/dt-investment) — Series A, Series C
- CKD Venture Capital (https://capitalatlas.ai/funds/ckd-venture-capital) — Series B, Series C
- BNK Venture Capital (https://capitalatlas.ai/funds/bnk-venture-capital) — Series B, Series C